Pfizer CEO: How AI Will Reshape the Future of Medicine | Podcast | In Good Company

Pfizer CEO Albert Bourla details the strategic evolution of the pharmaceutical giant, emphasizing a transition toward high-impact scientific innovation and organizational resilience. Following the pandemic-driven surge and subsequent revenue normalization, the company has prioritized R&D focus and targeted acquisitions like Seagen and Metsera to strengthen its oncology and obesity pipelines. AI integration serves as a critical lever for accelerating drug discovery and operational efficiency, necessitating widespread AI literacy across the workforce. Bourla identifies China’s rapid scientific output as a significant competitive challenge, arguing that U.S. entities must prioritize out-innovation over defensive measures. Central to his leadership philosophy is the cultivation of a high-performance culture, where optimism and adaptability are essential for navigating industry disruptions and maintaining a competitive edge in a rapidly evolving global healthcare landscape.